Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.

Economides MP, Verstovsek S, Pemmaraju N.

Curr Hematol Malig Rep. 2019 Aug 1. doi: 10.1007/s11899-019-00538-4. [Epub ahead of print] Review.

PMID:
31372878
2.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F.

Cancer. 2019 Jul 16. doi: 10.1002/cncr.32387. [Epub ahead of print]

PMID:
31310323
3.

Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia.

Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju N.

Leuk Lymphoma. 2019 Jul 15:1-2. doi: 10.1080/10428194.2019.1639171. [Epub ahead of print] No abstract available.

PMID:
31305193
4.

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.

Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR.

Haematologica. 2019 Jul 11. pii: haematol.2019.223503. doi: 10.3324/haematol.2019.223503. [Epub ahead of print]

5.

Dual Expression of TCF4 and CD123 is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.

Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD.

Am J Surg Pathol. 2019 Jun 28. doi: 10.1097/PAS.0000000000001316. [Epub ahead of print]

PMID:
31261288
6.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553. [Epub ahead of print]

PMID:
31237017
7.

Treatment advances in blastic plasmacytoid dendritic cell neoplasm.

Pemmaraju N.

Clin Adv Hematol Oncol. 2019 Apr;17(4):207-209. No abstract available.

PMID:
31188810
8.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W.

N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

PMID:
31141631
9.

Topoisomerase II inhibitors in AML: past, present, and future.

Economides MP, McCue D, Borthakur G, Pemmaraju N.

Expert Opin Pharmacother. 2019 May 28:1-8. doi: 10.1080/14656566.2019.1621292. [Epub ahead of print]

PMID:
31136213
10.

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, Yin CC, Konopleva M, Zheng X, Wang J, Tang Z, Medeiros LJ, Prieto VG, Pemmaraju N, Khoury JD.

Cancers (Basel). 2019 May 19;11(5). pii: E695. doi: 10.3390/cancers11050695.

11.

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M.

N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.

PMID:
31018069
12.

Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms.

Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA.

Hematol Oncol. 2019 Apr 23. doi: 10.1002/hon.2622. [Epub ahead of print]

PMID:
31013548
13.

Patient with mixed-phenotype acute leukemia with CBFB rearrangement.

Tallis E, Loghavi S, Jorgensen JL, Wang S, Khoury JD, Bueso-Ramos CB, Jain N, Borthakur G, Pemmaraju N.

Leuk Lymphoma. 2019 Apr 23:1-3. doi: 10.1080/10428194.2019.1605069. [Epub ahead of print] No abstract available.

PMID:
31012358
14.

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.

Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A.

J Geriatr Oncol. 2019 Apr 17. pii: S1879-4068(19)30033-5. doi: 10.1016/j.jgo.2019.04.002. [Epub ahead of print]

PMID:
31005650
15.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM.

Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.

PMID:
30985931
16.

Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia.

Alfayez M, Ivan D, Pemmaraju N, Daver N, DiNardo CD.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00198. Epub 2019 Feb 6. No abstract available.

17.

SMAC mimetics as potential cancer therapeutics in myeloid malignancies.

Boddu P, Carter BZ, Verstovsek S, Pemmaraju N.

Br J Haematol. 2019 Apr;185(2):219-231. doi: 10.1111/bjh.15829. Epub 2019 Mar 5. Review.

PMID:
30836448
18.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.

Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S.

Cancer. 2019 Jun 1;125(11):1855-1866. doi: 10.1002/cncr.31986. Epub 2019 Feb 27.

PMID:
30811597
19.

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.

Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S.

Blood. 2019 May 23;133(21):2348-2351. doi: 10.1182/blood-2019-01-897637. Epub 2019 Feb 22. No abstract available.

PMID:
30796023
20.

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms.

Pemmaraju N, Konopleva M, Lane AA.

N Engl J Med. 2019 Feb 14;380(7):695-6. doi: 10.1056/NEJMc1814963. No abstract available.

PMID:
30785714
21.

A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure.

Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD.

Leuk Lymphoma. 2019 Feb 18:1-7. doi: 10.1080/10428194.2019.1576873. [Epub ahead of print]

PMID:
30773968
22.

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F.

Blood Cancer J. 2019 Jan 16;9(2):7. doi: 10.1038/s41408-019-0170-3.

23.

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.

Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN.

Blood Cancer J. 2019 Jan 15;9(2):4. doi: 10.1038/s41408-018-0165-5.

24.

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.

Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S.

Leuk Lymphoma. 2019 Jul;60(7):1767-1774. doi: 10.1080/10428194.2018.1543876. Epub 2019 Jan 11.

PMID:
30632841
25.

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.

Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J.

J Hematol Oncol. 2019 Jan 3;12(1):1. doi: 10.1186/s13045-018-0686-1.

26.

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F.

Lancet Haematol. 2019 Jan;6(1):e29-e37. doi: 10.1016/S2352-3026(18)30182-0. Epub 2018 Dec 10.

PMID:
30545576
27.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H.

Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.

PMID:
30501869
28.

Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation.

Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N.

J Clin Pathol. 2019 Mar;72(3):251-257. doi: 10.1136/jclinpath-2018-205399. Epub 2018 Nov 22.

PMID:
30467242
29.

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H.

Cancer Discov. 2019 Mar;9(3):370-383. doi: 10.1158/2159-8290.CD-18-0774. Epub 2018 Nov 8.

PMID:
30409776
30.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community.

Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA.

Curr Hematol Malig Rep. 2018 Dec;13(6):581-587. doi: 10.1007/s11899-018-0490-6. Review.

PMID:
30338458
31.

Early detection of transformation to BPDCN in a patient with MDS.

Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB.

Exp Hematol Oncol. 2018 Oct 6;7:26. doi: 10.1186/s40164-018-0117-6. eCollection 2018.

32.

Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm.

Guru Murthy GS, Pemmaraju N, Atallah E.

Leuk Res. 2018 Oct;73:21-23. doi: 10.1016/j.leukres.2018.08.014. Epub 2018 Aug 24. No abstract available.

PMID:
30189324
33.

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N.

Blood. 2018 Oct 18;132(16):1664-1674. doi: 10.1182/blood-2018-04-846626. Epub 2018 Sep 5.

34.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.

Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.

35.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H.

Lancet Haematol. 2018 Sep;5(9):e411-e421. doi: 10.1016/S2352-3026(18)30132-7. Epub 2018 Aug 13.

PMID:
30115541
36.

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia.

Abaza Y, Cortes J, Ravandi F, Kadia T, Garcia-Manero G, Pemmaraju N, Shetty A, Pierce S, Qiao W, Kantarjian HM, Borthakur G.

Am J Hematol. 2018 Nov;93(11):E357-E360. doi: 10.1002/ajh.25240. Epub 2018 Sep 9. No abstract available.

PMID:
30074261
37.

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM.

Acta Haematol. 2018;140(1):30-39. doi: 10.1159/000490092. Epub 2018 Aug 2.

38.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.

Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD.

Blood Adv. 2018 Aug 14;2(15):1807-1816. doi: 10.1182/bloodadvances.2018019224.

39.

The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.

Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S.

Ann Hematol. 2018 Nov;97(11):2071-2080. doi: 10.1007/s00277-018-3402-x. Epub 2018 Jun 27.

PMID:
29951914
40.

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.

Cancer. 2018 Jul 1;124(13):2740-2747. doi: 10.1002/cncr.31357. Epub 2018 May 3.

41.

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K.

J Clin Oncol. 2018 Jun 20;36(18):1788-1797. doi: 10.1200/JCO.2017.77.6757. Epub 2018 Apr 27.

42.

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G.

Cancer. 2018 Jul 1;124(13):2758-2765. doi: 10.1002/cncr.31398. Epub 2018 Apr 16.

43.

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z.

Ann Hematol. 2018 Jul;97(7):1183-1191. doi: 10.1007/s00277-018-3289-6. Epub 2018 Mar 20.

44.

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J.

Lancet Haematol. 2018 Apr;5(4):e136-e146. doi: 10.1016/S2352-3026(18)30021-8. Epub 2018 Mar 14.

PMID:
29550383
45.

L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia.

Rausch CR, Paul S, Marx KR, Jabbour E, Pemmaraju N, Ferrajoli A, Kantarjian H.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):e191-e195. doi: 10.1016/j.clml.2018.02.014. Epub 2018 Feb 26. No abstract available.

PMID:
29550108
46.

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G.

Oncotarget. 2018 Jan 3;9(11):9714-9727. doi: 10.18632/oncotarget.23882. eCollection 2018 Feb 9.

47.

8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms.

Boddu PC, Wang SA, Pemmaraju N, Tang Z, Hu S, Li S, Xu J, Medeiros LJ, Tang G.

Leuk Res. 2018 Mar;66:73-78. doi: 10.1016/j.leukres.2018.01.013. Epub 2018 Feb 3.

PMID:
29407586
48.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E.

Lancet Oncol. 2018 Feb;19(2):240-248. doi: 10.1016/S1470-2045(18)30011-1. Epub 2018 Jan 16.

PMID:
29352703
49.

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.

Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S.

Eur J Haematol. 2018 Mar;100(3):257-263. doi: 10.1111/ejh.13005. Epub 2018 Jan 17.

50.

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M.

Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23.

Supplemental Content

Loading ...
Support Center